Genespire, an Italian biotechnology company developing gene therapies for paediatric patients suffering from genetic diseases, executed a EUR 46.6 million Series B capital increase round, one of the largest private investments in Italian biotech companies.

The investment was jointly led by Sofinnova Partners, XGEN Venture and CDP Venture Capital, forming a strong syndicate with Indaco SGR.

Genespire was advised in the transaction by PedersoliGattai in the persons of Nicola Brunetti (partner), Enrico Candotti (counsel) and Jacopo Cioffi (associate).